• head_banner_01

PriceList for Tacrolimus - Desmopressin Acetate to Treat central Diabetes Insipidus – Gentolex

Short Description:


Product Detail

Product Tags

Related Video

Feedback (2)

"Control the standard by the details, show the power by quality". Our business has strived to establish a highly efficient and stable team staff and explored an effective good quality regulate course of action for Sodium(+)-10-Camphorsulfonate, 4-Methoxy-Benzylamine, Glucosamine Sulphate Potassium Chloride, Good quality and competitive prices make our products enjoy a high reputation all over the word.
PriceList for Tacrolimus - Desmopressin Acetate to Treat central Diabetes Insipidus – Gentolex Detail:

Product Detail

Name  Desmopressin
CAS number  16679-58-6
Molecular formula  C46H64N14O12S2
Molecular weight  1069.22
EINECS Number  240-726-7
Specific rotation  D25 +85.5 ± 2° (calculated for the free peptide)
Density  1.56±0.1 g/cm3(Predicted)
RTECS No.  YW9000000
Storage conditions  Store at 0°C
Solubility  H2O:soluble20mg/mL, clear, colorless
Acidity coefficient  (pKa) 9.90±0.15 (Predicted)

Synonyms

MPR-TYR-PHE-GLN-ASN-CYS-PRO-D-ARG-GLY-NH2; MINIRIN; [DEAMINO1, DARG8] VASOPRESSIN; [DEAMINO-CYS1, D-ARG8]-VASOPRESSIN; DDAVP, HUMAN; DESMOPRESSIN; DESMOPRESSIN, HUMAN; DESAMINO-[D-ARG8] VASOPRESSIN

Indications

(1) Treatment of central diabetes insipidus. After the drug can reduce urinary excretion, reduce urinary frequency and reduce nocturia.

(2) Treatment of nocturnal enuresis (patients aged 5 years or older).

(3) Test the renal urine concentration function, and carry out the differential diagnosis of renal function.

(4) For hemophilia and other bleeding diseases, this product can shorten the bleeding time and prevent bleeding. It can reduce the amount of intraoperative blood loss and postoperative oozing; especially in conjunction with reasonably controlled blood pressure during surgery, it can reduce intraoperative bleeding from different mechanisms, and reduce postoperative oozing, which can play a better role in blood protection.

Treatment of diabetes insipidus

Diabetes insipidus is primarily a disorder of water metabolism characterized by excess urine output, polydipsia, hypoosmolarity, and hypernatremia. Partial or complete deficiency of vasopressin (central diabetes insipidus), or renal insufficiency of vasopressin (nephrogenic diabetes insipidus) can be onset. Clinically, diabetes insipidus is similar to primary polydipsia, a condition in which excessive fluid intake is caused by a malfunction of the regulatory mechanism or abnormal thirst. Contrary to primary polydipsia, the increase in water intake in patients with diabetes insipidus is a corresponding response to changes in osmotic pressure or blood volume.


Product detail pictures:

PriceList for Tacrolimus - Desmopressin Acetate to Treat central Diabetes Insipidus – Gentolex detail pictures

PriceList for Tacrolimus - Desmopressin Acetate to Treat central Diabetes Insipidus – Gentolex detail pictures


Related Product Guide:

Our organization has been focusing on brand strategy. Customers' gratification is our greatest advertising. We also source OEM provider for PriceList for Tacrolimus - Desmopressin Acetate to Treat central Diabetes Insipidus – Gentolex , The product will supply to all over the world, such as: South Korea, Belgium, Uruguay, To let customers be more confident in us and get the most comfortable service, we run our company with honesty, sincerity and best quality . We firmly believe that it is our pleasure to help customers to run their business more successfully, and that our professional advice and service can lead to more suitable choice for the customers.
  • The company can keep up with the changes in this industry market, product updates fast and the price is cheap, this is our second cooperation, it's good.
    5 Stars By Gabrielle from Seattle - 2018.07.27 12:26
    Production management mechanism is completed, quality is guaranteed, high credibility and service let the cooperation is easy, perfect!
    5 Stars By Fay from Auckland - 2018.08.12 12:27
    Write your message here and send it to us